United Therapeutics (NASDAQ:UTHR) Upgraded at StockNews.com

United Therapeutics (NASDAQ:UTHRGet Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Wednesday.

UTHR has been the topic of several other reports. HC Wainwright restated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. Wells Fargo & Company raised their price objective on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. SVB Leerink initiated coverage on United Therapeutics in a research note on Monday, February 5th. They set an “outperform” rating and a $330.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $294.40.

View Our Latest Research Report on United Therapeutics

United Therapeutics Price Performance

United Therapeutics stock opened at $228.58 on Wednesday. The stock has a market capitalization of $10.76 billion, a price-to-earnings ratio of 11.52 and a beta of 0.52. United Therapeutics has a 52-week low of $204.44 and a 52-week high of $261.54. The stock’s 50 day moving average price is $226.46 and its two-hundred day moving average price is $227.62. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41.

United Therapeutics (NASDAQ:UTHRGet Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The firm had revenue of $614.70 million for the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company’s revenue for the quarter was up 25.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.67 EPS. On average, equities analysts predict that United Therapeutics will post 23.46 earnings per share for the current year.

Insider Activity at United Therapeutics

In related news, Director Nilda Mesa sold 325 shares of the business’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total value of $77,285.00. Following the sale, the director now directly owns 5,373 shares in the company, valued at approximately $1,277,699.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Martine A. Rothblatt sold 14,125 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $236.18, for a total transaction of $3,336,042.50. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at $30,703.40. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Nilda Mesa sold 325 shares of the company’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total value of $77,285.00. Following the sale, the director now owns 5,373 shares in the company, valued at $1,277,699.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 91,130 shares of company stock worth $21,299,958. Company insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of UTHR. Wellington Management Group LLP increased its position in shares of United Therapeutics by 73.7% during the first quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock valued at $300,585,000 after buying an additional 710,668 shares during the period. Norges Bank purchased a new position in shares of United Therapeutics during the fourth quarter worth about $100,519,000. State Street Corp grew its holdings in shares of United Therapeutics by 15.9% during the first quarter. State Street Corp now owns 1,795,102 shares of the biotechnology company’s stock worth $402,031,000 after purchasing an additional 245,747 shares in the last quarter. BlackRock Inc. grew its holdings in shares of United Therapeutics by 5.4% during the first quarter. BlackRock Inc. now owns 4,751,961 shares of the biotechnology company’s stock worth $1,064,249,000 after purchasing an additional 241,594 shares in the last quarter. Finally, Avidity Partners Management LP purchased a new position in shares of United Therapeutics during the fourth quarter worth about $52,158,000. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.